Overview

A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes

Status:
Completed

Trial end date:
2017-12-21

Target enrollment:

Participant gender:

Summary

This is a bicentric, double-blinded, randomised, four-period crossover phase 1 trial, using automated 30-hour euglycemic clamp in subjects with type 2 diabetes mellitus.

Phase:

Phase 1

Details

Lead Sponsor:

Adocia

Treatments:

Biphasic Insulins
Insulin Lispro
Insulin, Isophane